Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Tariq_Kassum
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
gptkb:cancer
autoimmune diseases single-cell RNA sequencing |
| gptkbp:foundedYear |
2018
|
| gptkbp:founder |
gptkb:Christoph_Lengauer
|
| gptkbp:fundedBy |
$65 million
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Celsius Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:Alexandria_Venture_Investments
gptkb:Casdin_Capital gptkb:Third_Rock_Ventures gptkb:GV gptkb:Heritage_Medical_Systems Section 32 |
| gptkbp:website |
https://www.celsiustx.com/
|
| gptkbp:bfsParent |
gptkb:Alexandria_Venture_Investments
gptkb:Mark_Leschly |
| gptkbp:bfsLayer |
6
|